The Universal Patient Language: A set of resources and tools to design patient communications that support better health literacy

被引:2
作者
Bartlett S. [1 ]
Dezii C. [2 ,3 ]
Sandt K. [3 ]
机构
[1] Bridgeable, 1179 King Street West, Toronto, M6K 3C5, ON
[2] Quality and Measure Development, Federal Executive Branch Strategy and State Government Affairs, Bristol-Myers Squibb
来源
Inf Serv Use | 2019年 / 1-2卷 / 69-78期
关键词
health literacy; healthcare communications; human-centered design; patient communications; service design; Universal Patient Language; UPL;
D O I
10.3233/ISU-180031
中图分类号
学科分类号
摘要
Recently, pharmaceutical companies have increased their focus on engaging with patients, following trends toward patient centricity and delivering services around individual drugs. Meanwhile, the U.S. Food and Drug Administration has released draft guidance on disclosing risk information in consumer-directed materials that recommends against verbatim presentations of the risk-related sections within prescribing information, as this may be of limited value to consumers who lack medical or scientific training. In this context, Bristol-Myers Squibb set out to build an organizational capability to communicate complex health topics to patients called the Universal Patient Language™, or UPL. In this report, the authors explore health literacy considerations within the pharmaceutical industry; introduce the UPL; explain how human-centered service design methods were deployed to build the UPL; and present two UPL case studies. © 2019 IOS Press and the authors. All rights reserved.
引用
收藏
页码:69 / 78
页数:9
相关论文
共 10 条
[1]  
Donohue J., A history of drug advertising: The evolving roles of consumers and consumer protection, Milbank Q, 84, 4, pp. 659-699, (2006)
[2]  
(2019)
[3]  
Barello S., Graffigna G., Vegni E., Patient engagement as an emerging challenge for healthcare services: Mapping the literature, Nurs Res Pract, (2012)
[4]  
Wenzel M., Henne N., Zollner Y., Beyond the pill: The move towards value-added services in the pharmaceutical industry, J. Med. Mark, 14, 2-3, pp. 91-98, (2014)
[5]  
(2019)
[6]  
(2019)
[7]  
(2019)
[8]  
(2019)
[9]  
(2019)
[10]  
(2019)